Abstract
Recovery of viable Chlamydia pneumoniae from atheromas of coronary heart diseases patients has initiated pilot studies to eradicate C. pneumoniae from vascular tissue by antibiotic treatment. To provide data for the selection of effective antibiotics, we investigated the in vitro activity of anti-chlamydial antibiotics to eliminate vascular strains of C. pneumoniae from coronary endothelial and smooth muscle cells, celltypes that are involved in the pathogenesis of atherosclerosis.
Methods. The susceptibility of the obligate intracellular chlamydiae was studied in primary coronary endothelial cells, smooth muscle cells and immortalized epithelial cells. Minimal inhibitory concentrations (MICs) were determined for ofloxacin, levofloxacin, trovafloxacin, moxifloxacin, erythromycin, azithromycin, roxithromycin, rifapentin and rifampin.
Results. In vitro, rifampin was the most effective drug overall. Moxifloxacin and trovafloxacin were as effective as the macrolides of which roxithromycin was the most active one.
Conclusions. Actively replicating C. pneumoniae can be eliminated in vitro from cell types, involved in the pathogenesis of atherosclerosis by various antibiotics. These data provide an experimental background for the selection of antibiotics in clinical eradication studies and will help to assess the potential success of prevention and eradication therapies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Maass M, Bartels C, Engel PM, Mamat U, Sievers HH. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. JACC 1998; 31: 827-832.
Grayston JT. Antimicrobial treatment trials for secondary prevention of coronary artery diseases events. Circulation 1999; 99: 1538-1539.
Gieffers J, Solbach W, Maass M. In vitro susceptibilities of Chlamydia pneumoniae strains recovered from atherosclerotic coronary arteries. Antimicrob Agents Chemother 1998; 42: 2762-2764.
Maass M, Gieffers J, Solbach W. Atherogenetically relevant cells support continuous growth of Chlamydia pneumoniae. Herz 2000; 25: 68-72.
Eliopoulos GM, Moellering RC. Antimicrobial combinations. In: Lorian V, ed. Antibiotics in Laboratory Medicine, Baltimore: Williams and Wilkins 1996: 330-393.
Schachter J. Rifampin in chlamydial infections. Rev Infect Dis 1983; 5( Suppl. 3): 562-564.
Woodcoock JM, Andrews JM, Boswell FJ, Brenwald NP, Wise R. In vitro activity of BAY 12-8039, a new Fluoroquinolone. Antimicrob Agents Chemother 1997; 41: 101-106.
Donati M, Rodriguez Fermepin M, Olmo A, Dapote L, Cevenini R. Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against chlamydia spp. J Antimicrob Chemother 1999; 43: 825-827.
Jones RB, Van Der Pol B, Johnson RB. Susceptibility of Chlamydia trachomatis to trovafloxacin. J Antimicrob Chemother 1997; 39( Suppl. B): 63-65.
Roblin PM, Kutlin A, Hammerschlag MR. In vitro activity of trovafloxacin against Chlamydia pneumoniae. Antimicrob Agents Chemother 1997; 41: 2033-2034.
Roblin PM, Hammerschlag MR. In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae. Antimicrob Agents Chemother 1998; 42: 951-952.
Freidank HM, Losch P, Vögele H, Wiedemann-Al-Ahmad M. In vitro susceptibilities of Chlamydia pneumoniae isolates from German patients and synergistic activity of antibiotic combinations. Antimicrob Agents Chemother 1999; 43: 1808-1810.
Jones RB, Ridgway GL, Boulding S, Hunley KL. In vitro activity of rifamycin alone and in combination with other antibiotics against Chlamydia trachomatis. Rev Infect Dis 1983; 5( Suppl. 13): 556-561.
Gieffers J, Füllgraf H, Jahn J, et al. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 2001; 103: 351-356.
Beatty WL, Byrne GI, Morrison RP. Morphologic and antigenetic characterization of interferon gamma-mediated persistent Chlamydia trachomatis infection in vitro. Proc Nat Acad Sci USA 1993; 90: 3998-4002.
Kutlin A, Roblin PM, Hammerschlag MR. In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model. Antimicrob Agents Chemother 1999; 43: 2268-2272.
Hammerschlag MR, Chirgwin K, Roblin PM, et al. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis 1992; 14: 178-182.
Roblin PM, Montalban G, Hammerschlag M. In vitro activities of POC-47116, a new quinolone; ofloxacin and sparfloxacin against Chlamydia pneumoniae. Antimicrob Agents Chemother 1994; 38: 1402-1403.
Simon C, Stille W, ed. Antibiotikatherapie in Klinik und Praxis. Stuttgart, New York: Schattauer, 1999.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gieffers, J., Solbach, W. & Maass, M. In Vitro Susceptibility and Eradication of Chlamydia Pneumoniae Cardiovascular Strains from Coronary Artery Endothelium and Smooth Muscle Cells. Cardiovasc Drugs Ther 15, 259–262 (2001). https://doi.org/10.1023/A:1011972424529
Issue Date:
DOI: https://doi.org/10.1023/A:1011972424529